Frontlight ResearchEarly access
CompletedNo phase
PHOTOFINISH: a Clinical Study To Evaluate The Efficacy And Safety Of the System VULNOFAST® Plus/VULNOLIGHT® In Addition To The Usual Care (UC) Vs UC Alone For The Treatment Of Infected Diabetic Foot Ulcers
Key facts
- Who runs it
- L.Molteni & C. dei F.lli Alitti-Soc. di Esercizio S.p.A.
- Where
- Italy7 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 78 people enrolled
- Started
- 14 Sept 2021
- Ended
- 7 Apr 2026
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Usual Care alone
- System VULNOFAST® plus / VULNOLIGHT® in addition to Usual Care
- Record updated
- 3 November 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 23 criteriaShow less
Other criteria
- Main Inclusion Criteria:
- Able and willing to give voluntary written informed consent. The ICF, must be signed before any study-related procedures and/or assessments are performed
- Outpatients or inpatients (male and female) of any ethnic origin, aged 18 years or over, diagnosed with type 1 or type 2 diabetes mellitus
- Glycaemic control confirmed by a glycated haemoglobin (HbA1c) levels ≤10% (86 mmol/mol), evaluated in the 3 months before enrolment or at Visit 1
- Fasting plasma glucose (FPG) less than 300 mg/dl
- A chronic diabetic foot ulcer (DFU) below the malleolus, with an area ≥ 2 and ≤ 40 cm2 and with a maximum diameter/length ≤ 10 cm measured by MolecuLight i:X medical device [note: chronic wound is defined as a wound that, after the normal clinical practice, does not start healing within 4 weeks or does not heal within 8 weeks]
- A diabetic foot wound with a depth equal or higher to grade 2 according to the category "Depth/tissue loss" of PEDIS, but not involving bone, diagnosed by clinical examination
- Presence of infected foot ulcer of grade 2 according to the category "Infection" of PEDIS, diagnosed by clinical examination
- Able to take oral medications
- Patients must be willing and able to comply with the protocol and study procedures; Main Exclusion Criteria:
- Patients unable to give written informed consent
- Females who are pregnant or lactating
- Females who are of child bearing potential and not taking adequate contraceptive precautions are excluded from the trial. Females of child bearing potential taking acceptable contraceptive precautions can be included
- Participation in any other clinical trial or currently receiving any other investigational product(s) within 30 days prior to Visit 1
- Ankle brachial systolic blood pressure index < 0.5 (Winsor Index) in the infected limb
- Ulcer probe to bone positive
- Any surgery planned during the study period (from ICF signature to last planned follow-up visit)
- Clinical diagnosis of peripheral vascular disease (PVD) requiring percutaneous or surgical revascularization
- Transcutaneous oximetry (TcPo2) measurement < 30 mmHg
- Use of any antibiotics (local or systemic) within 48h before Visit 1
- Patient for whom punch biopsy is contraindicated
- Patients that cannot take amoxicillin and clavulanic acid (background antibiotic therapy) at the dosage stated in the protocol and according to the current Summary of Product Characteristics (SPC)
- Patients that cannot be treated with topical antiseptic containing Iodopovidone and/or with iodopovidone impregnated gauze according to the contraindication available in the current Summary of Product Characteristics (SPC)
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The aim of this randomised, open-label, multicentre clinical trial is to evaluate the superiority of the treatment which foresees the addition of the system VULNOFAST® plus / VULNOLIGHT® to the Usual Care, versus the treatment with Usual Care alone, for the healing of chronic diabetic foot ulcer. VULNOFAST® plus is a sterile solution used in combination with a red light source VULNOLIGHT®. Usual Care is defined as procedures to apply to the foot ulcer, carried out in the order in which they are listed in the protocol.
The 2 groups in the trial
- Arm A: Usual Care aloneExisting treatment, for comparison
Treatment: Usual Care alone
- Arm B: system VULNOFAST® plus / VULNOLIGHT® in addition to Usual CareTreatment being tested
Treatment: System VULNOFAST® plus / VULNOLIGHT® in addition to Usual Care
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Randomised, Open-Label, Multicentre Clinical Study To Evaluate The Efficacy And Safety Of Topical Applications Of the System VULNOFAST® Plus / VULNOLIGHT® In Addition To The Usual Care Versus Usual Care Alone For The Treatment Of Infected Foot Ulcers In Diabetic Patients (PHOTOFINISH)
- Record updated
- 3 November 2026